Impact of intravenous exenatide infusion for perioperative blood glucose control on myocardial ischemia-reperfusion injuries after coronary artery bypass graft surgery: sub study of the phase II/III ExSTRESS randomized trial

What Was Tested

The paper reports a study of Exenatide, published as a randomized controlled trial.

The aim of the study was to investigate whether intravenous (iv) infusion of exenatide, a synthetic GLP-1 receptor agonist, could provide a protective effect against myocardial ischemia-reperfusion injury after coronary artery bypass graft (CABG) surgery.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

A sub study analysis of patients > 18 years admitted for elective CABG and included in the ExSTRESS trial was conducted.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

All serum levels of troponin I measured during routine care in the Cardiac Surgery ICU were recorded.

The primary outcome was the highest value of plasma concentration of troponin I measured between 12 and 24 h after ICU admission.

What Was Measured

The subject headings attached to it are Biomarkers, Blood Glucose, Coronary Artery Bypass, Exenatide, France, Hypoglycemic Agents and Incretins.

Author keywords: Cardioprotective effects, Glucagon-like peptide 1 and Myocardial reperfusion injury.

What This Means in Plain Language

The paper is a randomized study of Exenatide.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2018 (Cardiovascular diabetology), a journal based in England.

More context: the Exenatide compound page, all human trials.